William Blair Sticks to Their Buy Rating for Aclaris Therapeutics Inc (ACRS)

By Austin Angelo

William Blair analyst Tim Lugo maintained a Buy rating on Aclaris Therapeutics Inc (ACRSResearch Report) on September 17. The company’s shares closed last Monday at $1.39, close to its 52-week low of $0.74.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 8.5% and a 38.8% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Collegium Pharmaceutical, and Acer Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aclaris Therapeutics Inc with a $5 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.98 and a one-year low of $0.74. Currently, Aclaris Therapeutics Inc has an average volume of 1.66M.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments.